Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?

Future Oncol. 2021 May;17(13):1577-1580. doi: 10.2217/fon-2020-1196. Epub 2021 Feb 16.
No abstract available

Keywords: Covalently closed circular DNA; OBI; Occult hepatitis B; cancer patients; immune checkpoint inhibitors; immunotherapy; prophylactic therapy; reactivation.

Publication types

  • Editorial

MeSH terms

  • Acute-On-Chronic Liver Failure / chemically induced
  • Acute-On-Chronic Liver Failure / epidemiology
  • Acute-On-Chronic Liver Failure / immunology*
  • Acute-On-Chronic Liver Failure / virology
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / epidemiology
  • Hepatitis B, Chronic / immunology*
  • Hepatitis B, Chronic / virology
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Immunocompromised Host
  • Latent Infection / chemically induced
  • Latent Infection / epidemiology
  • Latent Infection / immunology*
  • Latent Infection / virology
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Prevalence
  • Virus Activation / drug effects

Substances

  • Immune Checkpoint Inhibitors